Incyte Corporation (INCY) Shares are Up 1.21%

Incyte Corporation (INCY) has been under a strong bear grip, hence the stock is down -9.59% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 0.7% in the past 1 week. The stock has risen by 1.21% in the past week indicating that the buyers are active at lower levels, but the stock is down -9.71% in the past 4 weeks.

The stock has recorded a 20-day Moving Average of 0.64% and the 50-Day Moving Average is 1.32%.The 200 Day SMA reached 1.59%. Incyte Corporation has dropped 4.06% during the last 3-month period . Year-to-Date the stock performance stands at -24.37%.


Incyte Corporation (NASDAQ:INCY): After opening at $81.14, the stock dipped to an intraday low of $80.5 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $82.65 and the buying power remained strong till the end. The stock closed at $82.02 for the day, a gain of 1.50% for the day session. The total traded volume was 1,131,127. The stocks close on the previous trading day was $80.81.

Incyte Corporation is a biopharmaceutical company focused on the discovery development and commercialization of small molecule drugs to treat serious unmet medical needs. The Companys compound JAKAFI (ruxolitinib) also known as INCB18424 and INC424 is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or highrisk myelofibrosis (MF) including primary MF postpolycythemia vera MF and postessential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor LY3009104 (INCB28050) , which is subject to a collaboration agreement with Eli Lilly and Company in , which Lilly received development and commercialization rights f

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.